Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Terrie Curran
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
gastrointestinal diseases
|
| gptkbp:foundedYear |
2018
|
| gptkbp:headquartersLocation |
gptkb:Florham_Park,_New_Jersey,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Phathom Pharmaceuticals
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:product |
vonoprazan
|
| gptkbp:publiclyTraded |
true
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
PHAT
|
| gptkbp:therapeuticArea |
gptkb:Helicobacter_pylori_infection
gptkb:erosive_esophagitis gptkb:GERD acid-related disorders |
| gptkbp:website |
https://www.phathompharma.com/
|
| gptkbp:bfsParent |
gptkb:Frazier_Healthcare_Ventures
|
| gptkbp:bfsLayer |
7
|